IPIC Message Board - Msg: 2784879

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

0.0%

Aug 15 3:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Trey Yon who wrote (888)	11/21/1997 7:26:00 AM
From: Pancho Villa	Read Replies (1) of 1359

TT: ITRC. Be careful. These analysts give buy ratings left and right! >>Enrollment has now surpassed the 2,000 mark (2,048 to be exact) and we continue to anticipate the premature halting of the study due to efficacy of the drug. << This is not my understanding. In the letter to stockholders in the last 10K they talk about the BEST study being long due to the objective of trying to measure the effect of the drug on patient survival. The higher enrollment would produce more reliable statistics but I am not so sure the duration of the study would be reduced so signifantly so as to have a "premature halting" just around the corner. Premature halting may still be a couple of years away. [assuming this analyst does not possess insider info.] I wonder where one could read about the preliminary assessment regarding efficacy of the drug. >>R&D burn for the quarter was $11.7 million and included an $11.0 one-time payment to US marketing partner Astra Merck<< As IPIC, ITRC belongs to an "exclusive" club of biotechs that pay the big buys to use their drugs instead of the other way around. Neat idea! Pancho PS: we should start an Intercardia thread to better discuss the company. Thanks for sharing the info.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next